Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Brain Neoplasms 1Advanced and/or Metastatic Solid Tumours 1

Interventions

Gemcitabine 22Fluorouracil 14Oxaliplatin 13Capecitabine 13Paclitaxel 12pembrolizumab 11Cisplatin 11Carboplatin 11Pemetrexed 10Leucovorin 9130-nm albumin-bound paclitaxel 9Ramucirumab 8zolbetuximab 7Albumin-Bound Paclitaxel 7trastuzumab deruxtecan 6Drug Therapy 5Docetaxel 5Bevacizumab 5Nivolumab 4Irinotecan 4vandetanib 3cemiplimab 3Everolimus 3EC145 3tislelizumab 2technetium 99m etarfolatide 2spartalizumab 2pralsetinib 2osimertinib 2nimotuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma × nimotuzumab × Clear all
NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed
104 enrolled
Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡